ATUM’s New Lock-In™ Platform Solves Bispecific Mispairing

2026-05-12 · Source: The AI Journal · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology · Depth: Advanced, quick

Summary

ATUM, a bioengineering and cell line development company, launched its Lock-In™ Bispecifics Platform on May 12, 2026, at the PEGS Boston Summit. This platform addresses critical challenges in bispecific antibody (bsAb) development, specifically complex molecular design, light-chain mispairing, and biophysical instability. The Lock-In™ platform utilizes an IgG-like architecture to minimize aggregation, increase stability, and improve expression, aligning closer to standard monoclonal antibody manufacturing processes. It eliminates light chain mispairing, a common cause of impurities, and enables stable cell lines to consistently generate titers exceeding 5 g/L. The platform also preserves the original binding affinity and developability of lead candidates by avoiding the need for common light chains.

Key takeaway

For biopharmaceutical companies developing bispecific antibodies, the Lock-In™ Bispecifics Platform offers a path to overcome common hurdles like mispairing and instability. You can expect improved expression, purity, and stability, potentially reducing development timelines by months. Consider evaluating this platform to accelerate your transition from antibody discovery to high-titer bispecific antibody manufacturing.

Key insights

ATUM's Lock-In™ platform simplifies bispecific antibody development using an IgG-like architecture for enhanced stability and manufacturability.

Principles

• IgG-like architecture improves bispecific antibody developability.
• Minimizing structural changes enhances molecular stability and expression.
• Avoiding common light chains preserves binding affinity.

Method

The Lock-In™ platform combines an IgG-like framework with lightningHEK™ transient expression to rapidly evaluate variable region mAb sequences across bispecific formats for developability and manufacturability.

In practice

• Achieve bispecific antibody titers over 5 g/L.
• Reduce aggregation and immunogenicity risks.
• Streamline purification processes.

Topics

• ATUM
• Lock-In™ Bispecifics Platform
• Bispecific Antibodies
• IgG-like Architecture
• Light Chain Mispairing

Best for: Domain Expert, Executive, Consultant

Related on AIssential

• Scaling antibody language models improves structure aware representation for antibody engineering — Scaling antibody language models with advanced tokenization improves structure-aware representation for engineering.
• Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026 — Cadonilimab, a bispecific antibody, shows significant survival and tumor control benefits in advanced pancreatic cancer.
• NomosLogic Brings Deterministic Molecular Medicine Infrastructure to BIO International Convention 2026 as Adverse Drug Reactions Continue to Cost $30 Billion and 100,000 American Lives Each Year — NomosLogic provides deterministic, cryptographically proven molecular medicine infrastructure to address adverse drug reactions caused by population-averaged data.
• Graph Therapeutics brings total funding to over $10M to advance precision immunology — AI-powered analysis of live patient cells, multi-omics data, and functional biology decodes immune dysfunction for precision immunology.
• APCyc: Property-Informed Design of Cyclic Peptides via Automated Cyclization — APCyc automates cyclic peptide design by inferring cyclization topology and optimizing multiple drug-like properties via Bayesian guidance.
• ConTact: Contact-First Antibody CDR Design via Explicit Interface Reasoning — Explicitly predicting antigen contacts before sequence design significantly improves antibody CDR design performance.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The AI Journal.